Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Oligodendroglioma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 11Radiotherapy 4Magnetic Resonance Spectroscopy 4Specimen Handling 3Radiation 3Blood Specimen Collection 3Bevacizumab 3tislelizumab 2pembrolizumab 2cemiplimab 2Surgical Procedures, Operative 2mirdametinib 1gallium maltolate 1fluzoparib 1florbetapir 1elemene 1X-Rays 1Vortioxetine 1Transurethral Resection of Bladder 1Spironolactone 1Spinal Puncture 1Sitagliptin Phosphate 1Sampling Studies 1Receptors, Interleukin-8B 1Radiotherapy, Intensity-Modulated 1Psychosocial Intervention 1Platinum 1Photons 1Photochemotherapy 1Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Glioblastoma × Eflornithine × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡